IN USA VI è UNA CLASS ACTION CHE INCOLPA IL GIGANTE MERCK DI AVER FALSIFICATO I DATI A PROPOSITO ANCHE DELLA INEFFICACIA DEL SUO VACCINO TRIVALENTE CONTRO LA PAROTITE.

LE PERPLESSITA' E LE ACCUSE VENGONO DALLA CONSIDERAZIONE CHE LA MERCK, ATTUALE FORNITORE USA PER MMR II, DALLE SUE ANALISI SOSTIENE CHE L'EFFICACIA

è DEL 95% ED OLTRE.

LE ACCUSE RICOLTE A MERCK EVIDENZIANO PERO' UNA ERRATA PROCEDURA DI VALUTAZIONE DELLA MERK.

INFATTI LA COPERTURA PER OLTRE IL 95% PER LA PAROTITE è A CARICO DEL VIRUS VACCINALE ( attenuated Jeryl Lynn strain virus )  E NON DI QUELLO NATURALE.


A PAGINA 16 DEL SEGUENTE DOCUMENTO DELLA CLASS ACTION TROVATE

http://probeinternational.org/library/wp-content/uploads/2014/09/chatom-v-merck.pdf


" A PRN test simply compares virus growth in the presence of the pre- and postvaccinated blood samples. The number of plaques (where the virus has grown) is compared to determine if the vaccine caused the child to develop a sufficient level of antibodies to neutralize the virus. Results are reported in terms of seroconversion. A seroconversion occurs when the pre-vaccination blood sample is "negative" (meaning, insufficient antibodies to neutralize the virus) and the post-vaccination sample is "positive" (meaning, sufficient antibodies to neutralize the virus). Seroconversion occurs, therefore, when a blood sample goes from "pre-negative" (insufficient antibodies) to "post-positive" (sufficient antibodies). Seroconversion in the lab is the best correlate for efficacy -- how successful the vaccine is at immunizing children. For the purposes of its testing, Merck was looking for a seroconversion rate of 95 percent or higher to support its original efficacy finding and the efficacy it continued to represent in its labeling. 43. While Merck's PRN test was modeled after the neutralizing test generally accepted in the industry, it diverged from this "gold standard" test in a significant way. It did not test the vaccine for its ability to protect against a wild-type mumps virus. A wild-type virus is a disease-causing virus. That is the type of real-life virus against which vaccines are generally tested. Instead, Merck tested the children's blood for its capacity to neutralize the attenuated Jeryl Lynn strain of the virus. This was the same mumps strain with which the children were vaccinated. The use of the attenuated Jeryl Lynn strain, as opposed to a virulent wild-type strain, subverted the fundamental purpose of the PRN test, which was to measure the vaccine's ability to provide protection against a disease-causing mumps virus that a child would actually face in real life. The end result of this deviation from the accepted PRN gold standard test was that Merck's test overstated the vaccine's effectiveness."



NELLA CLASS ACTION SI FA RIFERIMENTO INFATTI AD UNA EPIDEMIA DI PAROTITE NEL 2006 CON OLTRE 6500 CASI ACCERTATI IN UNA POPOLAZIONE ALTAMENTE 

VACCINATA CON MMR II CON ALMENO DUE DOSI.

NEL 2006 A CAPO DEL CDC USA VI ERA LA DR.SSA JULIE GERBERDING CHE DIFESE IL VACCINO DELLA MERCK DALL'ACCUSA DI ESSERE INEFFICACE.

A PAG. 30 DEL  DOCUMENTO SOPRA INDICATO  TROVATE

"During the investigation of the outbreak, the CDC's then Director, Julie Gerberding, reaffirmed the CDC's view that nothing was wrong with the Mumps Vaccine, a belief fed by

Merck's continued misrepresentations: "We have absolutely no information to suggest that there is any problem with the vaccine." Director Gerberding and the CDC emphasized

that "[tlhe best protection against the mumps is the vaccine."

ALLA FINE DEL 2009 LA DR.SSA GERBERDING FU SOSTITUITA DA OBAMA. 

A FINE 2009 ERA A CAPO DELLA SEZIONE VACCINI DELLA MERCK.



A VOI I COMMENTI DEL CASO


FONTI

CLASS ACTION 12/3555

http://probeinternational.org/library/wp-content/uploads/2014/09/chatom-v-merck.pdf

http://www.merck.com/about/leadership/executive-committee/home.html

https://en.wikipedia.org/wiki/Julie_Gerberding